Cytokinetics INC Form 4 insider transactions

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports the exercise of stock options and subsequent sale of shares on June 11, 2024.

Director Muna Bhanji sold 2,000 shares of Cytokinetics Inc. (CYTK) at a price of $52.07 on June 10, 2024.

Cytokinetics' CEO, Robert I. Blum, sold 22,500 shares of common stock at $48.85 per share on June 4, 2024, under a pre-arranged 10b5-1 trading plan.

Robert Arthur Harrington, a director at Cytokinetics Inc, sold 1,580 shares of common stock at a price of $48.64 per share on June 3, 2024.

Director Lynne Parshall exercised stock options and sold shares of Cytokinetics Inc. on June 3, 2024.

EVP and CFO of Cytokinetics, Sung Lee, reports acquisition of restricted stock units and non-qualified stock options.

Robert Wong, VP, Chief Accounting Officer of Cytokinetics Inc, sold 13,011 shares of common stock on June 3, 2024, at a price of $48.88 per share.

Director Muna Bhanji reports acquisition and disposal of Cytokinetics Inc. common stock and acquisition of non-qualified stock options.

Director Santo J. Costa reports acquisition and disposal of Cytokinetics Inc. common stock and acquisition of non-qualified stock options.

Director Robert Arthur Harrington reports acquisition of Cytokinetics shares and stock options on May 15, 2024.

Director John T. Henderson reports acquisition and disposal of Cytokinetics Inc. common stock and acquisition of non-qualified stock options.

Director Edward M. Kaye reported acquiring 5,600 shares of Cytokinetics common stock and disposing of 24,917 shares, along with acquiring options to purchase 3,636 shares.

Director Lynne Parshall reported the acquisition and disposal of Cytokinetics Inc. common stock and stock options on May 15, 2024.

Wendell Wierenga, a director at Cytokinetics Inc, reported acquiring 5,600 shares of common stock and 3,636 non-qualified stock options on May 15, 2024.

Director Nancy Wysenski reports acquisition of Cytokinetics stock and stock options.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Director John T. Henderson sold 10,562 shares of Cytokinetics Inc. common stock at $64.54 per share on April 25, 2024, under a pre-arranged 10b5-1 trading plan.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reported a gift of 150 shares of common stock on April 12, 2024.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on April 9, 2024.

Cytokinetics' VP, Chief Accounting Officer Robert Wong, reports the acquisition of restricted stock units and stock options.

EVP and Chief Commercial Officer of Cytokinetics, Andrew Callos, reports the acquisition of restricted stock units and stock options.

EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports the acquisition of restricted stock units and stock options.

Robert Blum, President & CEO of Cytokinetics, reports acquisition of restricted stock units and stock options.

Robert Wong, VP, Chief Accounting Officer of Cytokinetics Inc., reports disposals of common stock to cover withholding obligations related to vesting Restricted Stock Units.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports the withholding of shares to cover tax obligations related to vesting Restricted Stock Units.

Cytokinetics' CEO, Robert Blum, reports the withholding of company shares to cover tax obligations related to vesting Restricted Stock Units.

EVP and Chief Commercial Officer of Cytokinetics, Andrew Callos, reports disposals of common stock to cover withholding tax obligations related to vesting Restricted Stock Units.

EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports the sale and acquisition of company stock and stock options on March 5, 2024, under a pre-arranged 10b5-1 trading plan.